TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study: NCT03466905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulant assessment
Study: NCT04654845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy
Description: Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ.
Study: NCT00120211

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy Fractionation
Description: Radiation Therapy 6 fractions per week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Radiotherapy Fractionation
Description: Radiotherapy 5 fractions per week
Study: NCT02755818

Intervention type: DRUG
Intervention: Heparin
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements

Intervention type: DRUG
Intervention: Heparin
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements

Intervention type: DRUG
Intervention: Heparin
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements

Intervention type: DRUG
Intervention: Heparin
Description: This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
Study: NCT03778268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: 1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining.
Study: NCT02782312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS+LABA
Description: Seretide is inhaled for one year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine therapy
Description: routine therapy for one year
Study: NCT02904070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal swabbing
Study: NCT04344080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb-Therapy
Description: Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
Study: NCT02604888

Intervention type: OTHER
Group type: OTHER
Intervention: MEXIS/M6S Patent - lotion against alopecia
Description: For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
Study: NCT01908192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaBen®
Description: The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
Study: NCT00929110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide
Description: Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to glycopyrronium bromide
Description: Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
Study: NCT04197739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram
Study: NCT00004242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT04606108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab in Combination With Neoadjuvant Chemotherapy
Description: camrelizumab in combination with Liposome doxorubicin and Ifosfamide
Study: NCT03720951

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pudendal nerve
Description: Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sacral n roots
Description: Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
Study: NCT02048423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
Study: NCT02334163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg nitazoxanide tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lactulose
Description: Oral lactulose (65%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lactulose
Description: Oral lactulose (65%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lactulose
Description: Oral lactulose (65%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 250 mg metronidazole tablets every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximine
Description: Two 200 mg rifaximine tablets every 8 hours
Study: NCT00933595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: A Motivational Interview session (\~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day.
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Study: NCT03186313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactavira Plus
Description: 1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Daclatasvir + Ribavirin
Description: Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactavira
Description: Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Daclatasvir
Description: Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
Study: NCT00435071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release Surgery
Description: Patient will have large incision size during carpal tunnel release surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have a small incision size during carpal tunnel release surgery.
Study: NCT01855958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIMST
Description: The investigators used electro acupuncture of 2 Hz during 30 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo-sham
Description: Electro acupuncture with rubber electrodes, without current passing.
Study: NCT04686916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2018
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2018
Description: Test drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02507570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: used concomitantly

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium ra 223 dichloride
Study: NCT03150082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR37547 tablet
Description: A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR37547 tablet
Description: A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin reference tablet
Description: A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin reference tablet
Description: A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side.
Study: NCT03208816

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: symptom management program for chemotherapy patients
Description: Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
Study: NCT04224246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma Hydroxybutyrate
Description: Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Study: NCT02941315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etiologic treatment,anti-myocardial remodeling
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-myocardial remodeling
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti-myocardial remodeling,anti-acute heart failure
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etiological, anti-remodeling and symptom treatment
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
Study: NCT03294642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potatoes
Description: Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Gel
Description: Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
Study: NCT04512963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: 100 mg/g nano-suspension for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: 100 mg/g nano-suspension for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A substance that has no therapeutic effect, used as a control in testing Progerinin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A substance that has no therapeutic effect, used as a control in testing Progerinin
Study: NCT03496389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 50mg QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol
Description: Panadol 500mg QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panadol
Description: Panadol 500mg QID
Study: NCT04339049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine spray
Description: four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
Study: NCT01944657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental TMS
Description: Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Monotherapy
Description: These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Monotherapy
Description: These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
Study: NCT03658291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanjin tablets
Description: Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sanjin tablets simulants
Description: levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
Study: NCT00898755

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03013400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebselen
Description: Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo is identical in appearance to the ebselen capsules
Study: NCT01608165

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical treatment for renal mass
Description: Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Radiofrequency ablation
Description: Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparascopic or percutaneous cryoablation
Description: Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
Study: NCT00003537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01868646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subetta
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT02208908

Intervention type: OTHER
Intervention: Evaluation of the oral conditionand proper care
Description: An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
Study: NCT02915939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Residential Care Transition Module
Description: Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.